|1.||Sacaan, Aida I: 1 article (10/2008)|
|2.||Correa, Lucia D: 1 article (10/2008)|
|3.||Adams, Pamala B: 1 article (10/2008)|
|4.||Cosford, Nicholas D P: 1 article (10/2008)|
|5.||Santori, Emily M: 1 article (10/2008)|
|6.||Rao, Tadimeti S: 1 article (10/2008)|
|7.||Reid, Richard T: 1 article (10/2008)|
|8.||Parkinson Study Group: 1 article (02/2006)|
|1.||Parkinson Disease (Parkinson's Disease)
08/01/1999 - "Thus, SIB-1508Y may be useful in the treatment of the cognitive deficits in Parkinson's disease."
10/09/2008 - "In rodents, SIB-1508Y exhibited antidepressant activity, reversed age-related decrements in vigilance, and improved motor and cognitive function in primate models of Parkinson's disease. "
02/14/2006 - "This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective alpha4beta2 nicotinic acetylcholine receptor agonist, in 77 individuals with early Parkinson disease. "
02/14/2006 - "Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease."
03/01/1998 - "These results suggest the potential usefulness of SIB-1508Y and levodopa as adjunctive therapies to improve at least some of the cognitive and motor deficits associated with Parkinson's disease."
|2.||Alzheimer Disease (Alzheimer's Disease)
|2.||nicotinic receptor alpha4beta2
|4.||Levodopa (L Dopa)
|6.||Ion Channels (Ion Channel)